Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Dora Menchaca"'
Autor:
Camille N. Abboud, Michael Macri, Scott E. Cruickshank, Dora Menchaca, Debra Frei-Lahr, Edmund K. Waller, Michael W. Schuster, Roy A. Beveridge, Jeannine T. Holden
Publikováno v:
Experimental Hematology. 30:1044-1050
To assess the safety and efficacy of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) administered after autologous bone marrow transplantation (ABMT).Two randomized, double-blind, placebo-controlled studies were
Autor:
Michael R. Green, Russell L. Basser, Dora Menchaca, Elizabeth O'Flaherty, Maria Edmonds, C. Glenn Begley, Brian Cohen, Janet L. Nichol
Publikováno v:
Blood. 99:2599-2602
Clinical trials of thrombopoietin (TPO), the central regulator of megakaryocytopoiesis, have revealed few side effects associated with its use. We here report a case of pancytopenia associated with the development of neutralizing antibodies to TPO th
Autor:
James J. Vredenburgh, John A. Glaspy, Brian J. Bolwell, L. Chap, Beth Overmoyer, Dora Menchaca, S. Cruickshank, C. Gilbert
Publikováno v:
Bone Marrow Transplantation. 26:141-145
Forty-seven patients with stage II, III, or IV breast cancer undergoing autologous peripheral blood progenitor cell (PBPC) transplantation were randomized to placebo (n = 13) or to one of five sequential dose cohorts of pegylated (PEG) recombinant hu
Autor:
Roy B. Jones, L. Chap, Ian McNiece, Elizabeth J. Shpall, William P. Sheridan, Michael Lill, C. F. LeMaistre, S. A. Turner, John A. Glaspy, M. D. Wiers, Dora Menchaca, Robert A. Briddell
Publikováno v:
Blood. 90:2939-2951
The safety and optimal dose and schedule of stem cell factor (SCF ) administered in combination with filgrastim for the mobilization of peripheral blood progenitor cells (PBPCs) was determined in 215 patients with high-risk breast cancer. Patients re
Autor:
Marc B. Garnick, Sharon A. Baughman, David Lau, Nick Fotheringham, Shekman L. Wong, Dora Menchaca
Publikováno v:
Journal of clinical pharmacology. 44(5)
This study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel depot formulation of abarelix, a new gonadotropin-releasing hormone (GnRH) antagonist. This was an open-label, sequential two-phase study in healthy male sub
Publikováno v:
Clinical pharmacology and therapeutics. 73(4)
Objectives Our objective was to evaluate the pharmacokinetic and pharmacodynamic characteristics of abarelix after continuous subcutaneous infusion of 50 μg · kg−1 · d−1 in patients with prostate cancer and to identify a plasma concentration o
Autor:
William P. Sheridan, Dora Menchaca
Publikováno v:
Stem cells (Dayton, Ohio). 16
Completed randomized placebo-controlled phase I/II studies of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) have demonstrated that this recombinant Mpl ligand has potent and lineage-dominant effects on megakary
Autor:
Howard Ozer, Michael Fanucchi, Laurence A. Harker, Jeffrey Crawford, Jennifer Garst, Robert A. Figlin, Dora Menchaca, William P. Sheridan, Dianne Tomita, John A. Glaspy
Publikováno v:
The New England journal of medicine. 336(6)
Polyethylene glycol (PEG)-conjugated recombinant human megakaryocyte growth and development factor (MGDF, also known as PEG-rHuMGDF), a recombinant molecule related to thrombopoietin, specifically stimulates megakaryopoiesis and platelet production a
Autor:
Jenny Marty, Dianne Tomita, John E.J. Rasko, Jonathan Cebon, Kerrie Clarke, Richard M. Fox, Sonay Hussein, C. Glenn Begley, Michael D. Green, Carole Alt, Russell L. Basser, Dora Menchaca
Publikováno v:
Lancet (London, England). 348(9037)
Summary Background Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) is a potent stimulator of megakaryocyte colony formation and platelet production. It is likely to be useful in the management of severe thrombocy
Autor:
Sherri Brown, George Morstyn, Ian McNiece, Michael Lill, Fred Lemaistre, Joseph Tami, John A. Glaspy, Roy B. Jones, Dora Menchaca, X. Q. Yan, Elizabeth J. Shpall, Robert A. Briddell
Publikováno v:
Journal of hematotherapy. 3(4)